相似文献
1
On the role of RNA binding proteins in polyglutamine diseases: from pathogenesis to therapeutics.
Neural Regen Res. 2023 Dec;18(12):2695-2696. doi: 10.4103/1673-5374.373711.
2
Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.
Brain. 2011 Jul;134(Pt 7):1943-58. doi: 10.1093/brain/awr146.
3
Polyglutamine disease: from pathogenesis to therapy.
S Afr Med J. 2012 Mar 2;102(6):481-4. doi: 10.7196/samj.5690.
4
CREB-binding protein sequestration by expanded polyglutamine.
Hum Mol Genet. 2000 Sep 1;9(14):2197-202. doi: 10.1093/hmg/9.14.2197.
5
Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration.
Mol Pharm. 2018 Dec 3;15(12):5781-5792. doi: 10.1021/acs.molpharmaceut.8b00938. Epub 2018 Nov 12.
6
[The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Mol Biol (Mosk). 2019 Nov-Dec;53(6):954-967. doi: 10.1134/S002689841906003X.
7
Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways.
J Biol Chem. 2004 Jan 30;279(5):3605-11. doi: 10.1074/jbc.M310939200. Epub 2003 Nov 5.
8
Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?
J Mol Cell Biol. 2010 Aug;2(4):180-91. doi: 10.1093/jmcb/mjq005. Epub 2010 Apr 21.
9
Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion.
Brain Sci. 2014 Mar 3;4(1):91-122. doi: 10.3390/brainsci4010091.
10
Protective effect of chaperones on polyglutamine diseases.
Brain Res Bull. 2001;56(3-4):165-8. doi: 10.1016/s0361-9230(01)00593-7.
本文引用的文献
1
The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
Brain. 2023 Jun 1;146(6):2346-2363. doi: 10.1093/brain/awac473.
2
Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapy.
Cell Death Dis. 2021 Nov 29;12(12):1117. doi: 10.1038/s41419-021-04404-1.
3
Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?
Cell Death Dis. 2021 Jun 8;12(6):592. doi: 10.1038/s41419-021-03873-8.
4
Stress granules and neurodegeneration.
Nat Rev Neurosci. 2019 Nov;20(11):649-666. doi: 10.1038/s41583-019-0222-5. Epub 2019 Oct 3.
5
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.
Neuron. 2019 Apr 17;102(2):294-320. doi: 10.1016/j.neuron.2019.03.014.
6
Spinocerebellar ataxia.
Nat Rev Dis Primers. 2019 Apr 11;5(1):24. doi: 10.1038/s41572-019-0074-3.
7
MSGP: the first database of the protein components of the mammalian stress granules.
Database (Oxford). 2019 Jan 1;2019. doi: 10.1093/database/baz031.
8
Polyglutamine Repeats in Neurodegenerative Diseases.
Annu Rev Pathol. 2019 Jan 24;14:1-27. doi: 10.1146/annurev-pathmechdis-012418-012857. Epub 2018 Aug 8.
9
Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
J Neurochem. 2019 Jan;148(1):8-28. doi: 10.1111/jnc.14541. Epub 2018 Oct 5.
10
Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
Brain. 2015 Dec;138(Pt 12):3537-54. doi: 10.1093/brain/awv298. Epub 2015 Oct 21.
Zotero 插件